Salut Sant Joan De Reus — Clinical Trial Site

76 Registered trials

35 Currently recruiting

Organisation

Salut Sant Joan De Reus

Location

Reus, Spain

Identifier

ORG-100043349

Address

Avinguda Del Doctor Josep Laporte 2, 43204, Spain

Departments

-
#3448: Medicina Interna
#4204:Servicio Medicina Interna
3113: medicina interna
3311: Oncology
4204: Unitat de Medicina Vascular i Metabolisme
7004:Oncología
Cardiology
Intensive care medicine
Lipidology
Medical oncologist
Medical Oncology
Medicina Interna
Medicina vascular y metabolismo
Medicine
N/A
Oncolgy
Oncologia
Oncología Radioterápica
Oncology
Oncology Department
Oncology Service
Planta baja. Unidad investigación- AULA 6
Radiotherapy oncology service
Servicio de Medicina Vascular y Metabolismo.
Servicio de Medicina Interna
Servicio de Oncología Médica
Servicio de Oncologia Medica y Radioterapia Àrea d´Oncologia / Unitat Recerca Clínica (URCO)
Servicio Ongología
Vascular and Metabolism Unit

Clinical trials at this site (76)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab… Pending

2024-516236-10-00 Triple-negative breast cancer 4
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending

2025-522204-24-00 Drug-Related Side Effects and Adverse Reactions 4
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting

2024-520027-88-00 Patients with hormone receptor-positive (HR+) breast ca 4 2026-02-12
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 HER2-positive early breast cancer 5 2025-11-26
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Non-small cell lung cancer 5 2026-03-05
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting

2025-521441-24-00 Advanced or Metastatic Solid Tumors 7 2026-01-19
Multicenter randomized clinical trial to evaluate two different amiodarone regimens to maintain sinus rhythm after cardioversion in persiste… Recruiting

2024-514113-35-01 Persistent atrial fibrillation 6 2025-11-03
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva… Recruiting

2024-515984-68-00 Non-small cell lung cancer (NSCLC) 4 2025-05-20
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 ROS1-positive non-small cell lung cancer (NSCLC) with a 4 2025-04-15
Study of treatment with sacituzumab and zimkberelimab for patients with lung cancer confined to the chest and previously operated on who wer… Recruiting

2024-512960-75-00 Resectable Non-small cell lung cancer 5 2025-02-04
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28